Immatics (IMTX) Osake Kurssi

Immatics NV is a clinical stage biopharmaceutical company based in Tuebingen, Germany, operating within the Health Care sector and specifically in the Biotechnology industry. The company focuses on the research and development of T cell receptor-based immunotherapies for cancer treatment. Immatics went public through an IPO on July 2, 2020, and currently employs 304 full-time staff. The company's therapeutic approach centers on developing T cell receptor therapies designed to elicit robust and specific immune responses against cancer targets. Immatics has a pipeline of eight therapeutic programs, four of which are in clinical trials. These include IMA201 targeting MAGEA4/8, IMA202 targeting MAGEA1, and ACTolog IMA 101, which is a multi-target pilot trial for solid cancers, as well as IMA203 for both hematological and solid cancers. The remaining four programs are in preclinical development, comprising IMA204 and IMA401 for solid cancers, and ACTallo IMA301 and IMA402 for both hematological and solid cancers. Immatics develops two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER), with a focus on treating solid tumors. The company's headquarters are located in Tuebingen, Baden-Wuerttemberg, Germany, and it maintains a website at https://immatics.com/ for further information.